Synchronous primary tumors of the kidney and the ovaries: Case report
Abstract
Synchronous primary tumors are a rare finding and that to dual malignancy involving the kidney and ovary is extremely rare. Diagnosing double malignancy is always a clinical challenge. Only a few cases are reported in the literature with synchronous primary malignancies of the kidney and the ovaries. We present a case of a 60- year-old lady, presenting with pain abdomen. Her reports showed a right kidney mass and ovarian mass which suggested it to be a metastatic case but after surgery immunohistochemistry (IHC) from the ovarian mass was immunoreactive to CK7, WT1, ER and nonimmunoreactive to CK20, RCC, CD10. Cells from the right kidney tumor were immunoreactive to PAX8 on the basis of IHC patient was diagnosed with bilateral ovarian adenocarcinoma and a simultaneous clear cell carcinoma of the right kidney. Right renal cell carcinoma was pT1bN0 whereas bilateral ovarian carcinoma was stage pT1cN0. As per current treatment guidelines, patient has been started on adjuvant chemotherapy.
Downloads
References
Vaslamatzis M, Alevizopoulos N, Petraki C, Vrionis E, Zoumblios C, Stassinopoulou P, et al. Second primary neoplasms (SPN) in cancer patients. Proc ASCO. 2003; 22:3581
Myoga H, Tamaki M, Shinko Y, et al. Synchronous double cancers in the ovary and kidney— a case report. Jpn Cancer Clin 1988;34:2007
Billroth T. Die Allgemeine Chirurgische Pathology and Therapy. In: Reimer G. 51 Vorlesungen-Ein Handbuch fur Studierende and Artze, 14. Berlin: Auflage, 1889.
Warren S, Gates O. Multiple primary malignant tumors: a survey of the literature and a statistical study. Am J Cancer 1932;16:1358–1414
Suzuki T, Takahashi H, Yao K, Inagi K, Nakayama M, Makoshi T, et al. Multiple primary malignancies in the head and neck: a clinical review of 121 patients. Acta Otolaryngol Suppl. 2002; (547):88- 92
Balat O, Kudelka AP, Ro JY, et al. Two synchronous primary tumors of the ovary and kidney: a case report. Eur J Gynaecol Oncol 1996; XVII:257–8
Einer RF, Neiberg RK, Berek JS. Synchronous primary neoplasms of the female reproductive tract. Gynecol Oncol 1989;33:335
Schottenfeld D, Berg J. Incidence of multiple primary cancers of the female breast and genital organs. J Natl Cancer Inst 1971;46: 161.
Di Silverio F, Sciarra A, Flammia GP, et al. Multiple primary tumors: 17 cases of renal cell carcinoma associated with primary tumors involving different steroidhormone target tissues. World J Urol 1997;15: 203–9
Concolino G, Marocchi A, Concolino F, et al. Human kidney steroid receptors. J Steroid Biochem 1996;10:831–5
Bursch W, Liehr JG, Sirbasku DA, et al. Control of cell death (apoptosis) by diethylstilbestrol in an estrogen-dependent kidney tumor. Carcinogenesis 1991;12:855–60
Banerjee SK, Banerjee S, Li SA, et al. Cytogenetic changes in the hamster renal tumor induced by estrogens. Proc Annu Meet Am Assoc Cancer Res 1991;32:967
Wong C, Plante M, and Eltabbakh G., Synchronous Renal Cell Carcinoma and Gynecologic Malignancies. Gynecologic Oncology 88, 66–68 (2003)
Raza MW, Verma S, Prasad SN et al. Recurrent Epitheloid Cell Sarcoma of Scapular region: A Case Report and Review of Literature. JMSCR 2019; 07(04):160-165
Xiang Li and Kong B. PAX8 is a novel marker for differentiating between various types of tumor, particularly ovarian epithelial carcinomas. Oncol Lett. 2013 Mar; 5(3): 735–738.
Kriplani D and Patel MM. Immunohistochemistry: A diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovary. South Asian J Cancer. 2013 Oct-Dec; 2(4):254–258.
Prat J (2012b) Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch.2012; 460(3): 237–249.
Beroukhim R, Brunet JP, Di Napoli A, et al.: Patterns of gene expression and copynumber alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009; 69(11): 4674–81
Motzer RJ, Jonasch E, Agarwal N, et al.: Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017; 15(6): 804–34.
Nickerson ML, Jaeger E, Shi Y, et al.: Improved identification of von HippelLindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14(15): 4726–34.
Musso C, Paraf F, Petit B, ArchambeaudMouveroux F, Valleix D, Lambrousse F. Tumeurs neuro-endocrines du pancréas et maladie de von Hippel-Lindau. Ann Pathol 2000;20:130–3
Brugarolas J: PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J. 2013; 19(4): 324–32
Rahman N, Stratton MR. The genetics of breast cancer susceptibility. Annu Rev Genet. 1998:32, 95–121
Pena-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al.: BAP1 loss defines a new class of renal cell carcinoma. Nat Genet. 2012; 44(7): 751–9.
